Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Wednesday

Posted by Brenda Bartman on May 6th, 2026

Fortress Biotech (NASDAQ:FBIO – Get Free Report) is anticipated to issue its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $16.3380 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Fortress Biotech (NASDAQ:FBIO – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.32). The firm had revenue of $16.08 million for the quarter, compared to the consensus estimate of $26.17 million. Fortress Biotech had a negative return on equity of 41.20% and a net margin of 10.77%. On average, analysts expect Fortress Biotech to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Fortress Biotech Trading Up 3.4%

Shares of FBIO stock opened at $2.46 on Wednesday. The firm has a market capitalization of $81.72 million, a P/E ratio of -18.92 and a beta of 1.16. Fortress Biotech has a twelve month low of $1.60 and a twelve month high of $4.53. The company has a quick ratio of 2.30, a current ratio of 2.49 and a debt-to-equity ratio of 0.84. The stock’s fifty day simple moving average is $2.79 and its 200 day simple moving average is $3.03.

Institutional Investors Weigh In On Fortress Biotech

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its position in shares of Fortress Biotech by 923.3% in the 3rd quarter. Bank of America Corp DE now owns 7,122 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 6,426 shares during the last quarter. Visionary Wealth Advisors bought a new stake in shares of Fortress Biotech during the 4th quarter valued at about $41,000. XTX Topco Ltd bought a new stake in shares of Fortress Biotech during the 2nd quarter valued at about $42,000. Osaic Holdings Inc. boosted its position in shares of Fortress Biotech by 18.4% during the 2nd quarter. Osaic Holdings Inc. now owns 32,379 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 5,034 shares in the last quarter. Finally, Scientech Research LLC bought a new stake in shares of Fortress Biotech during the 3rd quarter valued at about $67,000. Institutional investors own 96.51% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Zacks Research lowered Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. Wall Street Zen lowered Fortress Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Fortress Biotech in a research report on Monday, February 23rd. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Fortress Biotech in a research report on Friday, March 27th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Fortress Biotech presently has an average rating of “Hold” and an average price target of $17.00.

View Our Latest Stock Report on FBIO

Fortress Biotech Company Profile

(Get Free Report)

Fortress Biotech, Inc is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.

Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies.